A compound selected from: a cyclic polypeptide of Formula: or a pharmaceutically acceptable salt thereof; wherein: A 1 is H or an acyl protected amine; R 1 is selected from the group consisting of the amino acid side chains of ALA, GLY, ACB, ACPE, APC, LYS, NVA, PRO, and TBG; R 2 is selected from the group consisting of the amino acid side chains of ALA and GLY; R 3 is selected from the group consisting of the amino acid side chains of 4SFPRO, AIB, AZE, 4RFPRO, DHPRO, 4DFPRO, PIP, PRO, HSE, SISQ, and RISQ; R 4 is selected from the group consisting of the amino acid side chains of ALA, HIS, GLY, and PRO; R 5 is selected from the group consisting of the amino acid side chains of TYR, 4CF, 4FF, MFF, CNPP, 2NA, 1NA, F3MF, PHE, PRO, and OMY; EP Patent Application No. 19823341.3 A 2 is absent or and P 1 is selected from the group consisting of H and acetyl; wherein each amino acid residue is optionally an N-methylated amino acid; wherein each amino acid residue can be the R or S-enantiomer configuration; or a cyclic polypeptide compound: 002, 029, 030, 031, 032, 033, 034, 035, 036, 037, 038, 039, 040, 041, 047, 048, 050, 051, 052, 053, 054, 057, 058, 061, 062, 063, 064, 065, 066, 068, 069, 070, 071, 081, 082, 083, 084, 085, 086, 087, 088, 089, 091, 092, 093, 094, 095, 103,117, 001, 004, 005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018, 019, 020, 0 21, 022, 023, 024, 025, 026, 027, 028, 042, 043, 044, 045, 046, 049, 055, 056, 059, 060, 06 7, 072, 073, 074, 075, 076, 077, 078, 079, 080, 090, 096, 097, 098, 099, 100, 101, 102,104, 105, 106, 108, 109, 110, 112, 113, 114, 115, 116, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, or 131, wherein the formulae of said compounds are depicted in Tables 1, 2 and/or 3, J or a pharmaceutically acceptable salt thereof. a cyclic polypeptide of Formula: or a pharmaceutically acceptable salt thereof; wherein: A 1 is H or an acyl protected amine; R 1 is selected from the group consisting of the amino acid side chains of ALA, GLY, ACB, ACPE, APC, LYS, NVA, PRO, and TBG; R 2 is selected from the group consisting of the amino acid side chains of ALA and GLY; R 3 is selected from the group consisting of the amino acid side chains of 4SFPRO, AIB, AZE, 4RFPRO, DHPRO, 4DFPRO, PIP, PRO, HSE, SISQ, and RISQ; R 4 is selected from the group consisting of the amino acid side chains of ALA, HIS, GLY, and PRO; R 5 is selected from the group consisting of the amino acid side chains of TYR, 4CF, 4FF, MFF, CNPP, 2NA, 1NA, F3MF, PHE, PRO, and OMY; A 1 is H or an acyl protected amine; R 1 is selected from the group consisting of the amino acid side chains of ALA, GLY, ACB, ACPE, APC, LYS, NVA, PRO, and TBG; R 2 is selected from the group consisting of the amino acid side chains of ALA and GLY; R 3 is selected from the group consisting of the amino acid side chains of 4SFPRO, AIB, AZE, 4RFPRO, DHPRO, 4DFPRO, PIP, PRO, HSE, SISQ, and RISQ; R 4 is selected from the group consisting of the amino acid side chains of ALA, HIS, GLY, and PRO; R 5 is selected from the group consisting of the amino acid side chains of TYR, 4CF, 4FF, MFF, CNPP, 2NA, 1NA, F3MF, PHE, PRO, and OMY; EP Patent Application No. 19823341.3 A 2 is absent or and P 1 is selected from the group consisting of H and acetyl; wherein each amino acid residue is optionally an N-methylated amino acid; wherein each amino acid residue can be the R or S-enantiomer configuration; or a cyclic polypeptide compound: 002, 029, 030, 031, 032, 033, 034, 035, 036, 037, 038, 039, 040, 041, 047, 048, 050, 051, 052, 053, 054, 057, 058, 061, 062, 063, 064, 065, 066, 068, 069, 070, 071, 081, 082, 083, 084, 085, 086, 087, 088, 089, 091, 092, 093, 094, 095, 103,117, 001, 004, 005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018, 019, 020, 0 21, 022, 023, 024, 025, 026, 027, 028, 042, 043, 044, 045, 046, 049, 055, 056, 059, 060, 06 7, 072, 073, 074, 075, 076, 077, 078, 079, 080, 090, 096, 097, 098, 099, 100, 101, 102,104, 105, 106, 108, 109, 110, 112, 113, 114, 115, 116, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, or 131, wherein the formulae of said compounds are depicted in Tables 1, 2 and/or 3, A 2 is absent or and P 1 is selected from the group consisting of H and acetyl; wherein each amino acid residue is optionally an N-methylated amino acid; wherein each amino acid residue can be the R or S-enantiomer configuration; or a cyclic polypeptide compound: 002, 029, 030, 031, 032, 033, 034, 035, 036, 037, 038, 039, 040, 041, 047, 048, 050, 051, 052, 053, 054, 057, 058, 061, 062, 063, 064, 065, 066, 068, 069, 070, 071, 081, 082, 083, 084, 085, 086, 087, 088, 089, 091, 092, 093, 094, 095, 103,117, 001, 004, 005, 006, 007, 008, 009, 010, 011, 012, 013, 014, 015, 016, 017, 018, 019, 020, 0 21, 022, 023, 024, 025, 026, 027, 028, 042, 043, 044, 045, 046, 049, 055, 056, 059, 060, 06 7, 072, 073, 074, 075, 076, 077, 078, 079, 080, 090, 096, 097, 098, 099, 100, 101, 102,104, 105, 106, 108, 109, 110, 112, 113, 114, 115, 116, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, or 131, wherein the formulae of said compounds are depicted in Tables 1, 2 and/or 3, J or a pharmaceutically acceptable salt thereof.